<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS:   A20 (TNFAIP3) is a nuclear factor-κB (NF-κB)-inducible component of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor and Toll-like receptor intracellular signal transduction </plain></SENT>
<SENT sid="1" pm="."><plain>It negatively regulates NF-κB, and has been identified as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor </plain></SENT>
<SENT sid="2" pm="."><plain>Several studies have described A20 inactivation by deletion of the A20 locus at 6q23, inactivating mutations, and/or methylation of the A20 promoter in various <z:hpo ids='HP_0002665'>lymphoma</z:hpo> entities </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS:   We generated a monoclonal antibody against the C-terminus of A20 (Ber-A20) and investigated full-length A20 expression of <z:mpath ids='MPATH_458'>normal</z:mpath> lymphoid tissue and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> for the first time </plain></SENT>
<SENT sid="4" pm="."><plain>We identified loss of A20 expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells of 24% of classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 27% of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 20% of <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, 19% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 13% of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 8% of primary mediastinal B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases by immunohistology </plain></SENT>
<SENT sid="5" pm="."><plain>Loss of A20 expression rarely occurred in T-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS:   Our data are in agreement with cytogenetic and molecular analyses </plain></SENT>
<SENT sid="7" pm="."><plain>Among 21 cases of ocular adnexal marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with known A20 mutation status, we detected complete absence of A20 expression, whereas cases with <z:mp ids='MP_0002169'>wild-type</z:mp> A20 were weakly A20-positive </plain></SENT>
<SENT sid="8" pm="."><plain>We demonstrate that A20 loss can be detected by immunohistology with a sensitivity similar to that of complex molecular and genetic methods </plain></SENT>
</text></document>